MedTrace Logo

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

NCT03005639 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-05-09

No results posted yet for this study

Summary

Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma

• To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma after 8 weeks of neoadjuvant vemurafenib and cobimetinib

Conditions

  • Stage IIIB-C Melanoma

Interventions

DRUG

Vemurafenib and Cobimetinib

All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Sekwon Jang, MD · Inova Schar Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-02-24
Completion
2018-02-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03005639 on ClinicalTrials.gov